The Biomarker Niche for Fibroblast Growth Factor 23 Testing in CKD
نویسندگان
چکیده
منابع مشابه
Fibroblast growth factor 23 and Inflammation in CKD.
BACKGROUND AND OBJECTIVES Levels of fibroblast growth factor 23 (FGF23) and inflammatory markers are commonly elevated in CKD, and each is associated with adverse clinical outcomes. This study tested the hypothesis that FGF23 is independently associated with inflammation in CKD. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS The association between levels of FGF23 and the inflammatory markers ...
متن کاملIs Fibroblast Growth Factor 23 the New Biomarker for Cardiovascular Mortality in Chronic Kidney Disease Patients?
phosphate co-transporters in the kidney’s proximal tubules [5] . It also directly suppresses renal 1α-hydroxylase, decreasing the rate at which 25-hydroxyvitamin D is converted to its active metabolite, 1,25(OH) 2 D 3 [5] . The serum concentration of FGF23 is also highly correlated with a patient’s cystatin C eGFR [4] . Lastly, FGF23 may cause left ventricular hypertrophy by inducing cardiac my...
متن کاملRationale and Approaches to Phosphate and Fibroblast Growth Factor 23 Reduction in CKD.
Patients with CKD often progress to ESRD and develop cardiovascular disease (CVD), yet available therapies only modestly improve clinical outcomes. Observational studies report independent associations between elevated serum phosphate and fibroblast growth factor 23 (FGF23) levels and risks of ESRD, CVD, and death. Phosphate excess induces arterial calcification, and although elevated FGF23 hel...
متن کاملFibroblast growth factor 23 and incident CKD in type 2 diabetes.
BACKGROUND AND OBJECTIVES High levels of fibroblast growth factor 23 are associated with accelerated progression of CKD. Whether high fibroblast growth factor 23 levels also predict incident CKD is uncertain. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS A prospective case-cohort study was conducted within the Action to Control Cardiovascular Risk in Diabetes Trial. The analytic sample consis...
متن کاملHow fibroblast growth factor 23 works.
There is a discontinuum of hereditary and acquired disorders of phosphate homeostasis that are caused by either high or low circulating levels of the novel phosphaturic hormone fibroblastic growth factor 23 (FGF23). Disorders that are caused by high circulating levels of FGF23 are characterized by hypophosphatemia, decreased production of 1,25-dihydroxyvitamin D, and rickets/osteomalacia. On th...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of the American Society of Nephrology
سال: 2014
ISSN: 1046-6673,1533-3450
DOI: 10.1681/asn.2014060621